Development of a Field-Ready Antimicrobial Wound Dressing for the Treatment of Vesicant Burns

Award Information
Agency:
Department of Defense
Branch
Office for Chemical and Biological Defense
Amount:
$749,790.00
Award Year:
2008
Program:
SBIR
Phase:
Phase II
Contract:
W81XWH-07-C-0063
Agency Tracking Number:
C071-113-0151
Solicitation Year:
2007
Solicitation Topic Code:
CBD07-113
Solicitation Number:
2007.1
Small Business Information
STRATATECH CORP.
505 S. Rosa Road, Suite 169, Madison, WI, 53704
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
Y
Duns:
160392168
Principal Investigator:
Barry Steiglitz
Molecular Biology Scienti
(608) 441-2750
bsteiglitz@stratatechcorp.com
Business Contact:
Robert Barnard
Vice President and Treasu
(608) 441-2750
rbarnard@stratatechcorp.com
Research Institution:
n/a
Abstract
Cutaneous wounds, such as those resulting from vesicant exposure and thermal injuries, provide an ideal environment for bacterial growth and the complications stemming from wound sepsis. The availability of ready-to-use, antimicrobial skin substitutes that are readily deployed in the field would provide immediate wound closure and reduce the incidence of infection in these wounds. To address these needs, Stratatech Corporation is developing a field-ready, tissue engineered antimicrobial therapeutic called EpiReadyDefense™ for treatment of vesicant, thermal and traumatic cutaneous injuries. This product is designed to contain elevated levels of naturally-occurring antimicrobial peptides in the context of a fully-stratified skin substitute that is ready to use and stable at ambient temperatures. During Phase II of the project, procedures will be developed to optimize Stratatech’s existing antimicrobial skin substitute for ambient storage. Efforts will focus on preserving tissue architecture and strength, as well as maintaining the antimicrobial properties required in the final product. The antimicrobial properties of EpiReadyDefense™ will be determined in an established animal model of burn wound infection. Phase II studies will also include preclinical, in vivo wound healing studies that will be required to support ultimate clinical evaluation and approval of EpiReadyDefense™ tissue.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government